AACR 2021 | NADIM: baseline ctDNA as a prognostic factor for PFS

Mariano Provencio, MD, PhD, Hospital Universitario Puerta de Hierro, Majadahonda, Spain, outlines the relationship between high levels of baseline circulating tumor DNA (ctDNA) and progression-free survival (PFS) in patients who are receiving neoadjuvant chemoimmunotherapy in the NADIM clinical trial (NCT03081689). Analysis of 42 pre-treatment plasma samples from patients with NSCLC who were treated with nivolumab in the NADIM trial reported that ctDNA levels at mutant allele frequency below 1% at baseline were associated with improved PFS. This interview took place at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021.